Skip to main content

Table 3 Baseline patient characteristicsa

From: Albumin treatment regimen for type 1 hepatorenal syndrome: a dose–response meta-analysis

Study Vasoconstrictor Age (y) Serum concentrationb MAP (mm Hg)
Randomized    Creatinine Bilirubin Albumin  
Alessandria et al., 2007 [18]c terlipressin 55.0 (6.9) 2.5 (1.0) 5.1 (3.5) 3.0 (0.3) 74.0 (10.4)
  noradrenaline 56.0 (9.5) 2.3 (0.6) 4.1 (3.2) 3.0 (0.6) 71.0 (6.3)
Martín-Llahí et al., 2008 [19]c terlipressin 59.0 (10.0) 3.6 (1.5) 18.1 (19.1) 3.0 (0.7) 73.0 (10.0)
Neri et al., 2008 [20] terlipressin 59.0 (4.0) 2.8 (1.1) 2.7 (0.3) 82.0 (2.0)
Sanyal et al., 2008 [21] terlipressin 50.6 (10.5) 4.0 (2.2) 15.0 (13.6) 2.6 (0.8) 75.5 (11.4)
Sharma et al., 2008 [22] terlipressin 47.8 (9.8) 3.0 (0.5) 7.6 (9.8) 2.6 (0.6) 81.4 (11.4)
  noradrenaline 48.2 (13.4) 3.3 (1.3) 5.2 (6.8) 2.4 (0.4) 78.2 (5.3)
Silawat et al., 2011 [27] terlipressin 3.0 (1.3) 3.4 (2.1) 2.4 (0.7) 67.6 (16.4)
Singh et al., 2012 [29] terlipressin 51.4 (11.6) 3.3 (0.7) 4.0 (2.6) 2.8 (0.4) 64.7 (11.9)
  noradrenaline 48.3 (11.6) 3.1 (0.7) 4.7 (5.7) 2.8 (0.2) 65.2 (10.2)
Tavakkoli et al., 2012 [30]c midodrine/octreotide 52.9 (12.6) 2.6 (0.8) 11.6 (12.2) 2.6 (0.3) 69.8 (7.1)
  noradrenaline 52.0 (12.9) 2.6 (0.7) 8.0 (7.8) 2.7 (0.2) 73.4 (6.7)
Prospective       
Angeli et al., 1999 [13] midodrine/octreotide 62.0 (6.7) 5.0 (2.0) 4.3 (2.9) 3.0 (0.2) 75.9 (6.7)
Uriz et al., 2000 [14]c terlipressin 54.0 (11.0) 3.9 (2.1) 14.0 (18.0) 3.2 (0.6) 68.0 (6.0)
Mulkay et al., 2001 [15] terlipressin 53.5 (5.1) 3.4 (0.5) 6.2 (6.3) 2.9 (0.3) 76.0 (5.0)
Wong et al., 2004 [17] midodrine/octreotide 55.2 (7.9) 2.9 (1.2) 3.0 (1.6) 3.2 (1.0) 80.6 (14.7)
Muñoz et al., 2009 [23] terlipressin 54.2 (21.5) 3.3 (5.9) 69.6 (29.6)
Rivero et al., 2010 [26] terlipressin
Salerno et al., 2011 [1] terlipressin 62.0 (7.6) 3.2 (1.2) 15.1 (10.1) 2.8 (0.4) 80.4 (8.2)
  midodrine/octreotide 62.0 (5.9) 3.2 (0.9) 15.1 (7.8) 2.8 (0.3) 80.4 (6.4)
Narahara et al., 2012 [28] terlipressin 59.1 (11.8) 3.0 (0.8) 9.4 (7.6) 2.5 (0.4) 74.0 (14.0)
Retrospective       
Moreau et al., 2002 [16] terlipressin 56.0 (10.0) 2.9 (1.1) 11.8 (12.9) 2.8 (0.7) 78.0 (20.0)
Skagen et al., 2009 [24] midodrine/octreotide 52.7 (10.6) 2.5 (1.3)
von Kalckreuth et al., 2009 [25] terlipressin 51.8 (9.4)
  1. aIndicated values are mean (standard deviation).
  2. bSerum creatinine and serum bilirubin in mg/dL and serum albumin in g/dL.
  3. cIndicated baseline data reported only in the aggregate for types 1 and 2 HRS. However, outcome data (HRS reversal/survival) were reported separately for patients with type 1HRS, and only those separate outcome data for type 1 HRS were used in the meta-analysis.
  4. Abbreviation: HRS, hepatorenal syndrome; MAP, mean arterial pressure.